Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Subscribe To Our Newsletter & Stay Updated
